+1 (561) 832 9277 icausa@icausa.org

2020 Fellowships

ICA USA has published the following list of Research Fellowships available for funding in 2020. 

Click this link to download a complete list of the 2020 fellowships available for funding.

For more information or individual fellowship abstracts please call ICA USA at 561-832-9277.

To have us contact you about funding a 2020 Fellowship, complete the Fellowship Inquiry Contact Form here.

Descriptions of 2020 Fellowships:

20200006
Dr. Liat Drucker, Meir Medical Center
Shuttle of Ribosomal Proteins from Multiple Myeloma (MM)-MSCS into MM cells: disease progression marker & novel therapeutic target.
FUNDED

20200007
Dr. Michael Blank, Bar-Ilan University
Investigating the Smurf2/lamin A axis in tumor cell biology to help develop new more efficient anticancer drugs & treatment strategies.
Funding Requested $22,000

20200010
Prof. Dan Gibson, The Hebrew University of Jerusalem
Novel multi-action anticancer agents. Plan is to combine 2 or 3 FDA approved anticancer drugs into a single molecule that remains intact until it meets the cancer cells.
FUNDED

20200011
Prof. Avi Hai-Hovav, The Hebrew University of Jerusalem
Elucidating the protective mechanisms by which Langerhans cells inhibit the development of oral squamous cell carcinoma.
FUNDED

20200012
Prof. Miriam Ben Arush, Rambam Medical Center
Your pain, my suffering: Can an integrative medicine consultation improve quality of life of the parents of a child recently diagnosed with cancer? A preference-controlled study.
Funding Requested $22,000

20200018
Prof Boaz Tirosh, The Hebrew University of Jerusalem
Improved efficacy of tyrosine kinase inhibitors by selective ER-retention.
FUNDED

20200019
Prof. Rina Rosen-Arbesfeld, Tel-Aviv University
Promoting personalized therapeutic intervention for Familial Adenomatous Polyposis (FAP) patients harboring APC nonsense mutations.
Funding Requested $22,000

20200021
Dr. Cohen Idan, Haemek Medical Center
Characterization of recurrent mutations in H2B histone variants as potential novel oncohistone mutations controlling human “jumping genes” in epithileal cancers including lung, breast, colon & ovarian carcinomas.
FUNDED

20200028
Prof. Gil Ast, Tel-Aviv University
Analysis of regulatory pathways leading to alternative splicing aberrations in breast cancer.
FUNDED

20200031
Prof. Ilanit Hasson-Ohayon, Bar-Ilan University
Couples communication about the cancer experience, support provision and recipient and psychological outcome of both partners: an electronic diary study.
Funding Requested $22,000

20200037
Dr. Yoni Haitin, Tel-Aviv University
Identifying GGPPS inhibitors for cancer treatment using a high-throughput molecular approach.
Funding Requested $22,000

20200042
Dr. Niv Pencovich, Tel-Aviv Sourasky Medical Center
The transcriptional expression pattern of Myeloid Derived Suppressor Cells (MDSCs) as a biomarker for colorectal cancer load response to therapy & recurrence.
FUNDED

20200043
Prof. Ziv Ben Arye, Sheba Medical Center
The direct effect of microbial alterations on the development of hepatocellular carcinoma (HCC), to better understand whether microbial alterations can lead to the development of HCC in the context of cirrhosis.
FUNDED

20200044
Prof. Yair Harishanu, Tel-Aviv Sourasky Medical Center
Spatial and dynamics of early B-cell receptor signaling and actin cytoskeleton in Chronic lymphocytic leukemia (CLL) cells.
Funding Requested $22,000

20200049
Dr. Shahar Lev-Ari, Tel-Aviv University
The effect of Inquiry based stress reduction (IBSR) intervention technique on quality of life, well-being, optimism & health behavior of BRCA1/2 carriers: A randomized controlled trial.
Funding Requested $22,000

20200052
Prof. Baruch Brenner, Rabin Medical Center Beilinson Campus
Phase II trial to evaluate the addition of nivolumab to neoadjuvant chemoradiation with FOLFOX for locally advanced rectal cancer.
Funding Requested $22,000

20200053
Dr. Ariel Stanhill, The Open University
Evaluating the cellular and pathological roles of RNF149 in Myeloproliferative Neoplasm (MPN) formation. MPN are a group of diseases characterized by abnormal proliferation of cells within the bone marrow.
FUNDED
Abstracts Available Page 2 of 6 2/10/2020

20200057
Prof. Moran Benhar, Technion-Israel Institute of Technology
Regulation of colon cancer cell apoptosis (regulated cell death) by hydrogen sulfide.
FUNDED

20200067
Dr. Noam Nissan, Sheba Medical Center
Delayed contrast-enhanced breast MRI: A new means of cancer detection, diagnosis and stratification.
FUNDED

20200076
Dr. Shifra Ash, Schneider Children’s Medical Center of Israel
Genetic analysis of sporadic differentiated thyroid cancer as a novel approach for management and prognosis – comparison between pediatric and adult patients.
FUNDED

20200079
Prof. Joel Yisraeli, The Hebrew University of Jerusalem
Small Molecule Inhibitors of the Oncofetal Protein, VICKZ1. VICZ proteins are RNA binding proteins & elevated levels of these increase the mortality rate in lung adenocarcinoma patients so we are testing a molecule that can inhibit binding of VICZ1.
Funding Requested $22,000

20200080
Prof. Nabiah Ayoub, Technion-Israel Institute of Technology
Exploiting the novel role of RBM6 in DNA double-strand break repair for targeting RBM6- deficient cancer cells. Novel gene RBM6 helps fix DNA lesions & the goal is to optimize cancer treatment by targeting RBM6 deficient cells.
Funding Requested $52,000 (Advanced Fellowship)

20200081
Dr. Elad Jacoby, Sheba Medical Center
Parameters of efficacy, toxicity and trafficking of CAR T cells treating Central Nervous System leukemia.
FUNDED

20200083
Dr. Meital Gal-Tanamy, Bar Ilan University
The involvement of EGFR signaling pathway in Hepatitis C virus-induced spread of liver cancer pre and post cure of infection.
Funding Requested $22,000

20200084
Prof. Moshe Kotler, The Hebrew University of Jerusalem
APOBEC3G promotes bone marrow cells genotoxic resistance and avoids pre-neoplastic initiation in mice.
Funding Requested $22,000

20200086
Prof. Miri Cohen, Haifa University
The role of psychological factors and stress-related biomarkers in the response to immunotherapy (PD1/PDL1 inhibitors) in patients with advanced cancer.
Funding Requested $22,000

20200088
Dr. Maayan Salton, The Hebrew University of Jerusalem
Epigenetic regulation of CD44 alternative splicing following serum-induction.CD44 is a cell surface signal transducing receptor that influences motility, cell survival and proliferation as well as the formation of tumor microenvironment. Alternative splicing can produce various isoforms of CD44 with properties that may have diverse effects on cancer progression.
Funding Requested $22,000

20200092
Prof. Chaya Brodie, Bar Ilan University
Exosomal non-coding RNAs as circulating biomarkers in meningiomas (brain tumors).
FUNDED

20200095
Dr. Assaf Bester, Technion-Israel Institute of Technology
Targeting non-coding RNAs that mediate leukemia maintenance and resistance to targeted therapy.
Funding Requested $22,000

20200096
Prof. Tali Haran, Technion-Israel Institute of Technology
Towards validating a new model for p53 “gain-of-function” in cancer.
Funding Requested $22,000

20200098
Dr. Shenhav Cohen, Technion-Israel Institute of Technology
Developing novel tailor made diets to tackle cancer-induced cachexia.
FUNDED

20200102
Prof. Angel Porgador, Ben-Gurion University of the Negev
Nanochip for personalized assessment of checkpoint immunotherapy. Goal is to develop chip technology to be used for assessment of patient sensitivity to specific immune checkpoint blockade before & during treatment.
Funding Requested $22,000

20200104
Dr. Ido Wolf, Tel Aviv Sourasky Medical Center
Activating mutations of the estrogen receptor: novel players in the formation of liver metastasis in breast cancer.
FUNDED

20200106
Dr. Dana Ishay-Ronen, Sheba Medical Center
Patient-derived breast cancer organoid platform to evaluate trans-differentiation.
FUNDED

20200111
Dr. Uri Ben- David, Tel-Aviv University
Identifying cellular vulnerabilities induced by the most common chromosomal change in breast cancer.
FUNDED

20200112
Dr. Tali Tavor-Re’em, Azrieli Academic College
Role of bioactive lipids in exosome secretion and metastatic niche formation in Ovarian Cancer.
Funding Requested $22,000

20200115
Prof. Drorit Neumann, Tel-Aviv University
Cannabinoid agonist raises hemoglobin levels: Implications for treating anemia in cancer.
Funding Requested $22,000

20200122
Dr. Hadar Zigdon-Giladi, Rambam Medical Center
Revealing the crosstalk between osteosarcoma and endothelial progenitor cells.
Funding Requested $22,000

20200128
Dr. Karin Weiss, Rambam Medical Center
Elucidating the role of CHD4 in serious endometrial carcinoma.
Funding Requested $22,000

20200132
Prof. Marcelo Ehrlich, Tel-Aviv University
Breached defenses: epigenetic silencing of immunity genes regulates oncolytic immune virotherapy raising prospects of combination therapy.
FUNDED
Abstracts Available Page 5 of 6 2/10/2020

20200134
Dr. Adir Shaulov, Hadassah Medical Center Ein Kerem Campus
Early integrative palliative care in multiple myeloma patients.
FUNDED

20200136
Prof. Shay Ben Aroya, Bar-Ilan University
Elucidating the mechanism leading to the chromosomal instability in colorectal cancer cells overexpressing APC11, the catalytic subunit of the anaphase-promoting complex/cyclosome (APC/C).
Funding Requested $22,000

For more information on fellowship funding please call our office at (561) 832-9277.